TipRanks
Sarepta Therapeutics (CH:AB3A)
:AB3A
Switzerland Market
AB3A
Sarepta Therapeutics
RESEARCH TOOLSreports

Sarepta Therapeutics (AB3A) Stock News & Sentiment

0 Followers
Buy Rating Reaffirmed on Elevidys Strength and Long-Term Growth Outlook; $35 Price Target Unchanged
Premium
Ratings
Buy Rating Reaffirmed on Elevidys Strength and Long-Term Growth Outlook; $35 Price Target Unchanged
3d ago
SRPT
Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating
Premium
Ratings
Elevidys ENDURE Study Shows Partial Risk Mitigation but Persistent Safety Concerns, Supporting Hold Rating
5d ago
SRPT
Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained
Premium
Ratings
Sell Rating Reaffirmed on Sarepta as Regulatory Uncertainty Persists; $13 Price Target Maintained
5d ago
SRPT
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
Premium
Company Announcements
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
10d ago
8K
SRPT
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
Premium
Ratings
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
25d ago
SRPT
Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged
Premium
Ratings
Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged
25d ago
SRPT
Sarepta’s ENHANCE Study: Post-Marketing Safety Push for ELEVIDYS Could Shape SRPT’s Next Leg
Premium
Company Announcements
Sarepta’s ENHANCE Study: Post-Marketing Safety Push for ELEVIDYS Could Shape SRPT’s Next Leg
1M ago
SRPT
More CH:AB3A News >

AB3A News on the Web

Buy Rating Reaffirmed on Elevidys Strength and Long-Term Growth Outlook; $35 Price Target Unchanged
TipRanks News
Bullish
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
TipRanks News
Neutral
Sarepta Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
Sarepta Stock Slides as Trial Fears Rattle Investors
TipRanks News
Bearish
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
TipRanks News
Bullish
FDA Win Sends Sarepta Soaring On Duchenne Gene Bet
TipRanks News
Bullish
Q2 2026 Sarepta Therapeutics Inc Earnings Call Transcript
GuruFocus News
Neutral
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)
TipRanks News
Bearish

News Score - Last 7 Days

Neutral
CH:AB3A
Sector Average
Media Buzz
This Week6 articles
Weekly Average4 articles
News Sentiment
This Week50%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

FAQ

What is CH:AB3A’s Media Buzz Sentiment?
6 articles about CH:AB3A were published this week. In an average week, 4 articles are published.
    What is CH:AB3A’s weekly average amount of articles?
    In an average week, 4 articles about CH:AB3A are published.
      What is CH:AB3A’s News Sentiment?
      50% of articles about CH:AB3A were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        SYRESpyre Therapeutics
        BAYRYBayer
        QTTBQ32 Bio
        CICigna
        ZYMEZymeworks
        Showing the stocks with the most bullish news sentiment over the past week